Stockscreener 앱 받기
5.36
3.42%
-0.19
시장 영업 전:
5.40
0.04
+0.75%
Achieve Life Sciences Inc 주식(ACHV)의 최신 뉴스
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits
Lakeside Advisors, INC.'s Achieve Life Sciences Inc(ACHV) Holding History - GuruFocus
[ARS] ACHIEVE LIFE SCIENCES, INC. SEC Filing - Stock Titan
Achieve Life Sciences (NASDAQ: ACHV) plans vote to double share authorization - Stock Titan
ACHV News | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
ACHV Stock Chart | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences (ACHV) director awarded 47,250 options at $5.24 strike - Stock Titan
Achieve Life (ACHV) director receives 47,250 options at $5.24 strike - Stock Titan
ACHIEVE Life Sciences (ACHV) director reports no beneficial ownership on Form 3 - Stock Titan
Achieve Life Sciences (ACHV) director Farrow files Form 3 with no share ownership - Stock Titan
Achieve Life Sciences, Inc. Announces Board Appointments - marketscreener.com
Achieve Life Sciences appoints two new directors to board and committees - Investing.com Nigeria
Achieve Life Sciences, Inc. Files Form 8-K Current Report with SEC on May 29, 2026 - Minichart
Achieve Life Sciences appoints two new directors to board and committees By Investing.com - Investing.com South Africa
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors - The Globe and Mail
[8-K] ACHIEVE LIFE SCIENCES, INC. Reports Material Event - Stock Titan
ACHV Technical Analysis | Trend, Signals & Chart Patterns | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences (ACHV) asks shareholders to double authorized common shares to 300M - Stock Titan
Achieve Life Sciences 4Q Loss/Shr 28c >ACHV - Moomoo
Achieve Life Sciences Completes Tech Transfer to Adare Pharma Solutions - Contract Pharma
[EFFECT] ACHIEVE LIFE SCIENCES, INC. SEC Filing - Stock Titan
Achieve Life Sciences Q1 2026 Earnings: Narrower-than-Expected Loss Drives OptimismEnergy Earnings Report - thelegaladvocate.com
Canaccord reiterates Achieve Life Sciences stock rating on safety data By Investing.com - Investing.com South Africa
Achieve Life Sciences (ACHV) price target decreased by 14.04% to 12.82 - MSN
Canaccord reiterates Achieve Life Sciences stock rating on safety data - Investing.com
Q3 2025 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
Achieve Life Sciences presents long-term cytisinicline data By Investing.com - Investing.com Australia
Achieve Life Sciences presents long-term cytisinicline data - Investing.com UK
Achieve Life Sciences, Inc.: cytisinicline data indicate well-tolerated safety over 52 weeks for adults quitting smoking - Traders Union
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment - The Manila Times
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline in Smoking Cessation at ATS 2026 - Quiver Quantitative
Achieve Life Sciences Q1 earnings call highlights - MSN
Achieve (ACHV) Q1 2026 Earnings Transcript - AOL.com
Q2 Earnings Forecast for ACHV Issued By Zacks Research - MarketBeat
Earnings call transcript: Achieve Life Sciences beats Q1 2026 EPS expectations - Investing.com Nigeria
Canaccord Genuity initiates coverage of Achieve Life Sciences (ACHV) with buy recommendation - MSN
HC Wainwright Has Optimistic Outlook of ACHV Q2 Earnings - MarketBeat
[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan
Director at ACHIEVE Life Sciences (ACHV) granted 47,250 stock options at $5.59 - Stock Titan
Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission - Seeking Alpha
Achieve Life Sciences, Inc.Common Shares (NQ: ACHV - FinancialContent
2.60%
0.94%
자본화:
|
볼륨(24시간):